Why is Marksans Pharma falling/rising?

As of 24-Jul, Marksans Pharma Ltd is experiencing a decline in its stock price, currently at Rs 231.80, which represents a decrease of Rs 6.35 or 2.67%. The stock has been underperforming significantly, having fallen consecutively for the last seven days, resulting in a total decline of 11.53% during this period. Additionally, it is trading below all its moving averages, indicating a bearish trend. Despite a high management efficiency reflected in a return on equity (ROE) of 17.66% and low debt-to-equity ratio, the company has shown poor long-term growth with an operating profit growth rate of only 2.87% over the last five years. The stock's valuation appears expensive compared to its peers, with a price-to-book value of 4.3, which may deter potential investors.
In the broader market context, the stock's performance has been notably weaker than the benchmark, as it has declined by 10.78% over the past week while the Sensex has only decreased by 0.09%. Year-to-date, Marksans Pharma has dropped 21.76%, contrasting sharply with the Sensex's gain of 5.18%. This stark difference highlights the stock's struggles relative to the market. Although there has been a rise in investor participation, with delivery volume increasing by 69.15% against the five-day average, the overall sentiment remains negative due to flat results and low inventory turnover ratios. Thus, the combination of poor recent performance, high valuation concerns, and lackluster growth prospects contributes to the stock's downward trajectory.